Search This Blog

Thursday, July 30, 2026

'Madrigal down after beat'

 

Madrigal Pharmaceuticals reports second-quarter loss of $1.99 per share and revenue of $364.3 million, both beating Wall Street expectations

  • Q2 2026 Rezdiffra net sales were $364.3 million, up 71% year over year.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)